The University of Chicago Header Logo

Connection

Mark J. Ratain to Etoposide

This is a "connection" page, showing publications Mark J. Ratain has written about Etoposide.
Connection Strength

1.449
  1. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
    View in: PubMed
    Score: 0.286
  2. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
    View in: PubMed
    Score: 0.134
  3. Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol. 1994; 34 Suppl:S64-8.
    View in: PubMed
    Score: 0.115
  4. New perspectives on the toxicity of etoposide. Semin Oncol. 1992 Dec; 19(6 Suppl 13):78-83.
    View in: PubMed
    Score: 0.107
  5. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst. 1991 Nov 06; 83(21):1560-4.
    View in: PubMed
    Score: 0.099
  6. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
    View in: PubMed
    Score: 0.097
  7. Dose reduction of etoposide in jaundiced patients. J Clin Oncol. 1990 Dec; 8(12):2088-9.
    View in: PubMed
    Score: 0.093
  8. Etoposide pathway. Pharmacogenet Genomics. 2009 Jul; 19(7):552-3.
    View in: PubMed
    Score: 0.084
  9. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar; 45(3):226-33.
    View in: PubMed
    Score: 0.082
  10. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
    View in: PubMed
    Score: 0.081
  11. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
    View in: PubMed
    Score: 0.075
  12. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
    View in: PubMed
    Score: 0.048
  13. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
    View in: PubMed
    Score: 0.036
  14. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol. 1996; 39(1-2):61-6.
    View in: PubMed
    Score: 0.033
  15. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther. 1995 Mar; 57(3):325-34.
    View in: PubMed
    Score: 0.031
  16. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993 Feb 03; 85(3):217-23.
    View in: PubMed
    Score: 0.027
  17. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.